The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Sundar Jagannath
Consultant or Advisory Role - Celgene; Merck Sharp & Dohme; Millennium; Onyx
Honoraria - Celgene; Merck Sharp & Dohme; Millennium; Onyx
Craig C. Hofmeister
Consultant or Advisory Role - Celgene
Research Funding - Celgene; Merck; Millennium; Oncolytics Biotech
Rachid C. Baz
Research Funding - Bristol-Myers Squibb; Celgene; Millennium; Sanofi
David Samuel DiCapua Siegel
Honoraria - Celgene; Merck; Millennium; Onyx
Ravi Vij
Consultant or Advisory Role - Celgene; Onyx
Honoraria - Celgene; Millennium; Onyx
Research Funding - Celgene; Onyx
Christine Chen
Honoraria - Celgene
Research Funding - Celgene
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Johnson & Johnson; Millennium; Novartis; Onyx; Sanofi
Kenneth Carl Anderson
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Millennium; Onyx
Other Remuneration - Acetylon Pharmaceuticals; OncoPep
Min Chen
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Mohamed H. Zaki
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium